The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study to evaluate the safety and efficacy of IMM-101 in combination with checkpoint inhibitors in patients with advanced melanoma: Final results of the IMM-101-015 trial.
 
Alberto Fusi
Honoraria - Bristol-Myers Squibb; Pierre Fabre
 
Avinash Gupta
Honoraria - Bristol-Myers Squibb; Novartis
 
Paul Lorigan
Honoraria - Amgen; BMS; Merck; MSD; Nektar; NeraCare GmbH; Novartis; Oncology Education; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Nektar; Novartis; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre
Research Funding - BMS
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Peter L Smith
No Relationships to Disclose
 
Mike Bowles
Employment - Diurnal
Stock and Other Ownership Interests - Diurnal